In the present article, we first compared IgG binding specificities of P354-14 and P338-16 using an ELISA method, and then analyzed the TSH-R SAb absorbing ability of both peptides using a preincubation method and an affinity absorption method with 18 Graves' IgGs.
Thyroid stimulating TSH receptor antibody (TSH-R SAb) has been postulated to play an important role in the development of Graves' disease (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Nagayama & Rapaport recently reported different recognition sites on the hTSH receptor among TSH-R SAb using a chimeric cDNA expression technique (18) .
We have also investigated the significance of a particular region of the hTSH receptor which is specific for this receptor and does not occur in the LH/CG or FSH receptor sequences (15, 19) . Synthetic oligopeptides, such as P-195 (P353-11, hereafter) and P-218 (P354-14) are known to bind TSH-R SAb specifically and thus to inhibit TSH-R SAb activity. Further, P354-14 and P338-16 (P-231 in Ref. 19 ) were shown to exert quite different absorbing effects on TSH-R SAb activity with a Graves' immuno¬ globulin, F-IgG (19). The TSH-R SAb activity was inhibited effectively by P354-14 but not affected by P338-16. In the present article, we first compared IgG binding specificities of P354-14 and P338-16 using an ELISA method, and then analyzed the TSH-R SAb absorbing ability of both peptides using a preincubation method and an affinity absorption method with 18 Graves' IgGs.
We were able to demonstrate heterogeneous recogni¬ tion of the hTSH receptor epitopes among these TSH-R SAb.
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